Skin cancers: malignant tumors arising from abnormal skin cells that invade surrounding tissue and can spread.
The FDA has approved bemotrizinol (BEMT) for over‑the‑counter sunscreens, marking a modernization in U.S. UV protection. The ingredient absorbs both UVA and UVB rays, is photostable, and will debut as Parsol Shield before broader market adoption after an 18‑month exclusivity period. Industry and dermatology experts say the move could improve protection and user experience, though rollout and formulation timelines remain.
The FDA has approved bemotrizinol, a chemical UV filter used in European and Asian sunscreens for over 20 years. It offers UVA and UVB protection, is photostable, and may lead to more elegant, higher-SPF products in the US. The move comes after decades of FDA inaction on new filters, with products containing bemotrizinol expected to reach US shelves after about 18 months.
Five or more sunburns raise melanoma risk by up to 80%, with age and burn severity shaping outcomes. Experts urge daily sunscreen and preventive care as cases rise across the United States.
A round-up of recent cancer-related reports shows patients benefiting from clinical trials and rare misdiagnoses being corrected. From rectal cancer trials in the UK to cervical cancer misdiagnoses under review, readers are kept informed on treatment advances and patient experiences.